Tags

Type your tag names separated by a space and hit enter

[The clinical value of tumor marker CA50 and CA242 in digestive tract cancer].
Zhongguo Yi Xue Ke Xue Yuan Xue Bao. 1998 Aug; 20(4):285-8.ZY

Abstract

OBJECTIVE

CA50 and CA242 are newly recognized serum tumor marker. This study is to show their value in the diagnosis of digestive tract tumor.

METHODS

164 patients with malignant digestive disease and 69 patients with benign disease were chosen. CA50 and CA242 level of these patients were measured by immunoradiometric assay.

RESULTS

The total sensitivity of CA50 and CA242 are 70% and 63% respectively. Two tumor markers rarely elevated in the patients with benign disease (false positive rate CA50 7.3%, CA242 4.3%). High percentage of elevated CA242 level was recorded in the patients with pancreatic and biliary cancers (Sensitivity 79%). Both have low sensitivity in patients with liver carcinoma.

CONCLUSIONS

CA50 and CA242 are valuable marker in the diagnosis of digestive tract tumor.

Authors+Show Affiliations

2nd Municipal Hospital of Shan Tou, Shan Tou 515011.No affiliation info availableNo affiliation info available

Pub Type(s)

English Abstract
Journal Article

Language

chi

PubMed ID

11367693

Citation

Huang, C, et al. "[The Clinical Value of Tumor Marker CA50 and CA242 in Digestive Tract Cancer]." Zhongguo Yi Xue Ke Xue Yuan Xue Bao. Acta Academiae Medicinae Sinicae, vol. 20, no. 4, 1998, pp. 285-8.
Huang C, Bei L, Liu T. [The clinical value of tumor marker CA50 and CA242 in digestive tract cancer]. Zhongguo Yi Xue Ke Xue Yuan Xue Bao. 1998;20(4):285-8.
Huang, C., Bei, L., & Liu, T. (1998). [The clinical value of tumor marker CA50 and CA242 in digestive tract cancer]. Zhongguo Yi Xue Ke Xue Yuan Xue Bao. Acta Academiae Medicinae Sinicae, 20(4), 285-8.
Huang C, Bei L, Liu T. [The Clinical Value of Tumor Marker CA50 and CA242 in Digestive Tract Cancer]. Zhongguo Yi Xue Ke Xue Yuan Xue Bao. 1998;20(4):285-8. PubMed PMID: 11367693.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - [The clinical value of tumor marker CA50 and CA242 in digestive tract cancer]. AU - Huang,C, AU - Bei,L, AU - Liu,T, PY - 2001/5/23/pubmed PY - 2001/6/22/medline PY - 2001/5/23/entrez SP - 285 EP - 8 JF - Zhongguo yi xue ke xue yuan xue bao. Acta Academiae Medicinae Sinicae JO - Zhongguo Yi Xue Ke Xue Yuan Xue Bao VL - 20 IS - 4 N2 - OBJECTIVE: CA50 and CA242 are newly recognized serum tumor marker. This study is to show their value in the diagnosis of digestive tract tumor. METHODS: 164 patients with malignant digestive disease and 69 patients with benign disease were chosen. CA50 and CA242 level of these patients were measured by immunoradiometric assay. RESULTS: The total sensitivity of CA50 and CA242 are 70% and 63% respectively. Two tumor markers rarely elevated in the patients with benign disease (false positive rate CA50 7.3%, CA242 4.3%). High percentage of elevated CA242 level was recorded in the patients with pancreatic and biliary cancers (Sensitivity 79%). Both have low sensitivity in patients with liver carcinoma. CONCLUSIONS: CA50 and CA242 are valuable marker in the diagnosis of digestive tract tumor. SN - 1000-503X UR - https://www.unboundmedicine.com/medline/citation/11367693/[The_clinical_value_of_tumor_marker_CA50_and_CA242_in_digestive_tract_cancer]_ L2 - https://medlineplus.gov/pancreaticcancer.html DB - PRIME DP - Unbound Medicine ER -